These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38583231)

  • 1. Semaglutide alters gut microbiota and improves NAFLD in db/db mice.
    Mao T; Zhang C; Yang S; Bi Y; Li M; Yu J
    Biochem Biophys Res Commun; 2024 May; 710():149882. PubMed ID: 38583231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semaglutide May Alleviate Hepatic Steatosis in T2DM Combined with NFALD Mice via miR-5120/ABHD6.
    Li R; Ye Z; She D; Fang P; Zong G; Hu K; Kong D; Xu W; Li L; Zhou Y; Zhang K; Xue Y
    Drug Des Devel Ther; 2022; 16():3557-3572. PubMed ID: 36238196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice.
    Liu Q; Cai BY; Zhu LX; Xin X; Wang X; An ZM; Li S; Hu YY; Feng Q
    Life Sci; 2020 Nov; 261():118457. PubMed ID: 32961235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
    Romero-Gómez M; Lawitz E; Shankar RR; Chaudhri E; Liu J; Lam RLH; Kaufman KD; Engel SS;
    J Hepatol; 2023 Oct; 79(4):888-897. PubMed ID: 37355043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.
    Volpe S; Lisco G; Fanelli M; Racaniello D; Colaianni V; Triggiani D; Donghia R; Crudele L; Rinaldi R; Sabbà C; Triggiani V; De Pergola G; Piazzolla G
    Nutrients; 2022 Nov; 14(21):. PubMed ID: 36364937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
    Soto-Catalán M; Opazo-Ríos L; Quiceno H; Lázaro I; Moreno JA; Gómez-Guerrero C; Egido J; Mas-Fontao S
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis.
    de Paiva IHR; da Silva RS; Mendonça IP; de Souza JRB; Peixoto CA
    J Neuroimmune Pharmacol; 2024 Jul; 19(1):36. PubMed ID: 39042202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes.
    Melander SA; Kayed A; Andreassen KV; Karsdal MA; Henriksen K
    Eur J Pharmacol; 2024 Jan; 962():176215. PubMed ID: 38056618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease.
    Zhou M; Liu X; Wu Y; Xiang Q; Yu R
    J Ethnopharmacol; 2024 Jul; 329():118160. PubMed ID: 38588985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota.
    Chen L-p; Zhang L-f; Liu S; Hua H; Zhang L; Liu B-c; Wang R-r
    Microbiol Spectr; 2024 Jun; 12(6):e0197923. PubMed ID: 38647315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Sesquiterpene Glycoside from Loquat Leaf Alleviates Type 2 Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease by Improving Insulin Resistance, Oxidative Stress, Inflammation, and Gut Microbiota Composition.
    Chen J; Ding X; Wu R; Tong B; Zhao L; Lv H; Meng X; Liu Y; Ren B; Li J; Jian T; Li W
    J Agric Food Chem; 2021 Dec; 69(47):14176-14191. PubMed ID: 34783554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.
    Patel Chavez C; Cusi K; Kadiyala S
    J Clin Endocrinol Metab; 2022 Jan; 107(1):29-38. PubMed ID: 34406410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
    Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
    Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
    Lin YH; Zhang ZJ; Zhong JQ; Wang ZY; Peng YT; Lin YM; Zhang HP; Tian JQ
    PLoS One; 2024; 19(5):e0302155. PubMed ID: 38701096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease.
    Rochoń J; Kalinowski P; Szymanek-Majchrzak K; Grąt M
    World J Gastroenterol; 2024 Jun; 30(23):2964-2980. PubMed ID: 38946874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
    Wang P; Wang J; Li D; Ke W; Chen F; Hu X
    J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice.
    Inia JA; Stokman G; Morrison MC; Worms N; Verschuren L; Caspers MPM; Menke AL; Petitjean L; Chen L; Petitjean M; Jukema JW; Princen HMG; van den Hoek AM
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SIRT2 Deficiency Aggravates Diet-Induced Nonalcoholic Fatty Liver Disease through Modulating Gut Microbiota and Metabolites.
    Li X; Du Y; Xue C; Kang X; Sun C; Peng H; Fang L; Han Y; Xu X; Zhao C
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.